Company intelligence / Profile preview

Targacept

Winston-Salem, North Carolina, United Statesir.catalystbiosciences.com ↗

Ownership: Private
Development stage: Other

Overview

Targacept developed a pipeline of small molecule drugs targeting neuronal nicotinic receptors for central nervous system and gastrointestinal indications. The company achieved positive Phase 2b results for TC-5214 as an adjunctive treatment for major depressive disorder and advanced several other candidates into clinical trials. However, after a series of failed late-stage trials and strategic shifts, the company was acquired by Catalyst Biosciences in 2015 via reverse merger.

Therapeutic areas: GastroenterologyPsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

ispronicline

4 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca (for AZD3480/TC‑1734 in ADHD)Rhone-Poulenc Rorer/Sanofi-aventis

Beyond the preview

Go deeper on Targacept.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Targacept.

Explore the full profile